Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVANA: Preoperative Chemoradiotherapy Plus Avelumab in Rectal Cancer
NCT03854799Phase 2Completed
- Sponsor
- Gruppo Oncologico Nord Ovest
- Start
- Apr 2019
- Primary completion
- Feb 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab in rectal cancer, sponsored by Gruppo Oncologico Nord Ovest. Primary endpoint: Complete Pathologic Response Rate at 24 months. Started Apr 2019; status: completed.
02
Drugs
avelumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT03854799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03854799.